Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials
Fred Yang,1 June Ye,2 Kenneth Pomerantz,3 Murray Stewart1 1Alternative Development Program, GlaxoSmithKline, King of Prussia, PA, 2Discovery Biometrics, GlaxoSmithKline, Research Triangle Park, NC, 3Clinical Development and Medical Affairs, Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-07-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
| Online Access: | http://www.dovepress.com/potential-modification-of-the-ukpds-risk-engine-and-evaluation-of-macr-a13655 |